Diligence memo · auto-generated · as of July 2, 2026

Innate Immunity Llc

Innate Immunity Llc looks under-valued against its niche peers and is dormant on financing cadence.

DeprioritizeFinancing has gone silent well past the sector's normal cadence — treat as inactive until outside confirmation of a live operation.

Businessfiled

Innate Immunity Llc operates in Biotechnology, based in SANTA FE.

No verified homepage on file yet — operating evidence is limited to the public record.

Capital & rounds (filed)filed

Innate Immunity Llc has raised $130K in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Pre-Seed (a round under $1.0M).

Largest single filing: $130K on 2020-09-01.

Most recent recorded round closed around 2020-09-01.

Valuation (modeled)modeled

Provath models Innate Immunity Llc at approximately $6.5M (range $69K–$70M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Read: Under-valued. Modeled value is 0.41× the median modeled value of Pre-Seed Biotechnology companies in 2019–2021 (156 peers) — value vs value, same stage and era.

Financing rhythm & timingmixed

Last raise 5.8 yr ago; this sector typically re-raises about every 14 months.

Only one round on record and long silent — often defunct, acquired, or gone quiet.

Comparablesmixed

Capital scale ranks ahead of 2% of Biotechnology peers (4293 compared).

Modeled value ranks above 13% of those peers.

Closest niche peers: Crimson BioPharm Inc., Pinpoint Therapeutics Inc., Transplant Logistics & Informatics Llc, RNAissance AG LLC, Pylum Biosciences, Inc..

Peoplefiled

1 named person on file across officers, directors and signatories.

Risks & flagsmixed

Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.